Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis

Ashish Kumar, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Vikas Singla, Shivam Khare, Abhishyant Srivastava, Ashish Kumar, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Vikas Singla, Shivam Khare, Abhishyant Srivastava

Abstract

Background: Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19.

Methods: We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods.

Results: We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity).

Conclusions: Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done.

Keywords: 2019-nCoV; COVID-19; Coronavirus; Diabetes mellitus; Novel coronavirus; SARS-CoV-2; nCoV-2019.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no conflicts of interest.

Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
PRISMA flow chart showing the flow of study selection.
Fig. 2
Fig. 2
Pooled proportion of diabetes mellitus in COVID-19 patients.
Fig. 3
Fig. 3
Forest plot showing pooled odds ratio of diabetes mellitus associated with severe clinical course including mortality.
Fig. 4
Fig. 4
Funnel plot for evaluation of publication bias.

References

    1. Coronavirus update (live): 2,818,181 cases and 196,576 deaths from COVID-19 virus pandemic - worldometer. n.d. (accessed April 25, 2020)
    1. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036. doi: 10.1136/bmj.m1036.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.
    1. Sun P., Qie S., Liu Z., Ren J., Li K., Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 doi: 10.1002/jmv.25735.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., Prisma Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
    1. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6 doi: 10.1371/journal.pmed.1000100.
    1. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc. 2000;283 doi: 10.1001/jama.283.15.2008. 2008–12.
    1. Wuhan Municipal Health Commission [Wuhan Municipal Health Commission on the current situation of pneumonia in our city] n.d. (accessed April 27, 2020)
    1. Bauchner H., Golub R.M., Zylke J. Editorial concern-possible reporting of the same patients with COVID-19 in different reports. J Am Med Assoc. 2020 doi: 10.1001/jama.2020.3980.
    1. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. n.d. (accessed March 28, 2020)
    1. State Administration of Traditional Chinese Medicine [Notice on the issuance of a new coronavirus infection pneumonia diagnosis and treatment plan (trial fifth version)] n.d. (accessed April 27, 2020)
    1. National Health Commission of the People’s Republic of China Diagnosis and treatment protocol for COVID-19 (trial version 7) n.d. (accessed April 27, 2020)
    1. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200:e45–e67. doi: 10.1164/rccm.201908-1581ST.
    1. Study Quality Assessment Tools National Heart, lung, and blood Institute (NHLBI) n.d. (accessed March 28, 2020)
    1. Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135.
    1. Freeman M.F., Tukey J.W. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607–611.
    1. DerSimonian R., Laird N. Meta-analysis in clinical trials. Contr Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    1. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
    1. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629.
    1. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463. doi: 10.1111/j.0006-341x.2000.00455.x.
    1. Wallace B.C., Dahabreh I.J., Trikalinos T.A., Lau J., Trow P., Schmid C.H. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Software. 2012;49:1–15. doi: 10.18637/jss.v049.i05.
    1. CDC Covid-19 Response Team Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, february 12-march 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:382–386. doi: 10.15585/mmwr.mm6913e2.
    1. Guan W.-J., Liang W.-H., Zhao Y., Liang H.-R., Chen Z.-S., Li Y.-M. Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis. Eur Respir J. 2020 doi: 10.1183/13993003.00547-2020.
    1. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 doi: 10.1007/s40618-020-01236-2.
    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843.
    1. Wang L., Gao P., Zhang M., Huang Z., Zhang D., Deng Q. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. J Am Med Assoc. 2017;317:2515–2523. doi: 10.1001/jama.2017.7596.
    1. Ceriello A., Stoian A.P., Rizzo M. COVID-19 and diabetes management: what should be considered? Diabetes Res Clin Pract. 2020:108151. doi: 10.1016/j.diabres.2020.108151.
    1. Wang B., Li R., Lu Z., Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12:6049–6057. doi: 10.18632/aging.103000.
    1. Singh A.K., Gupta R., Ghosh A., Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303–310. doi: 10.1016/j.dsx.2020.04.004.
    1. Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319. doi: 10.1002/dmrr.3319.
    1. Yang J.K., Feng Y., Yuan M.Y., Yuan S.Y., Fu H.J., Wu B.Y. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23:623–628. doi: 10.1111/j.1464-5491.2006.01861.x.
    1. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. J Am Med Assoc. 2003;289:2801–2809. doi: 10.1001/jama.289.21.JOC30885.
    1. Dodek P. Diabetes and other comorbidities were associated with a poor outcome in the severe acute respiratory syndrome. ACP J Club. 2004;140:19.
    1. Matsuyama R., Nishiura H., Kutsuna S., Hayakawa K., Ohmagari N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Publ Health. 2016;16:1203. doi: 10.1186/s12889-016-3881-4.
    1. Yang Y.-M., Hsu C.-Y., Lai C.-C., Yen M.-F., Wikramaratna P.S., Chen H.-H. Impact of comorbidity on fatality rate of patients with Middle East respiratory syndrome. Sci Rep. 2017;7:11307. doi: 10.1038/s41598-017-10402-1.
    1. Kulcsar K.A., Coleman C.M., Beck S.E., Frieman M.B. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4 doi: 10.1172/jci.insight.131774.
    1. Angelidi A.M., Belanger M.J., Mantzoros C.S. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metab Clin Exp. 2020:154245. doi: 10.1016/j.metabol.2020.154245.
    1. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Drucker D.J. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020 doi: 10.1210/endrev/bnaa011.
    1. Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125. doi: 10.1016/j.diabres.2020.108125.
    1. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008:CD006739. doi: 10.1002/14651858.CD006739.pub2.
    1. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc. 2007;298:194–206. doi: 10.1001/jama.298.2.194.
    1. Yang W., Cai X., Han X., Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016;32:391–404. doi: 10.1002/dmrr.2723.
    1. Gupta R., Ghosh A., Singh A.K., Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14:211–212. doi: 10.1016/j.dsx.2020.03.002.
    1. Hill M.A., Mantzoros C., Sowers J.R. Commentary: COVID-19 in patients with diabetes. Metab Clin Exp. 2020;107:154217. doi: 10.1016/j.metabol.2020.154217.
    1. Misra A., Gopalan H., Jayawardena R., Hills A.P., Soares M., Reza-Albarrán A.A. Diabetes in developing countries. J Diabetes. 2019;11:522–539. doi: 10.1111/1753-0407.12913.
    1. Hills A.P., Arena R., Khunti K., Yajnik C.S., Jayawardena R., Henry C.J. Epidemiology and determinants of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol. 2018;6:966–978. doi: 10.1016/S2213-8587(18)30204-3.
    1. Misra A., Tandon N., Ebrahim S., Sattar N., Alam D., Shrivastava U. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ. 2017;357:j1420. doi: 10.1136/bmj.j1420.
    1. Singh A.K., Gupta R., Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020;14:283–287. doi: 10.1016/j.dsx.2020.03.016.
    1. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017.
    1. Ghosh A., Gupta R., Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: guidelines for physicians. Diabetes Metab Syndr. 2020;14:273–276. doi: 10.1016/j.dsx.2020.04.001.
    1. Critchley J.A., Carey I.M., Harris T., DeWilde S., Hosking F.J., Cook D.G. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41:2127–2135. doi: 10.2337/dc18-0287.
    1. Mor A., Dekkers O.M., Nielsen J.S., Beck-Nielsen H., Sørensen H.T., Thomsen R.W. Impact of glycemic control on risk of infections in patients with type 2 diabetes: a population-based cohort study. Am J Epidemiol. 2017;186:227–236. doi: 10.1093/aje/kwx049.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. J Am Med Assoc. 2020 doi: 10.1001/jama.2020.1585.
    1. Zhang J.-J., Dong X., Cao Y.-Y., Yuan Y.-D., Yang Y.-B., Yan Y.-Q. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 doi: 10.1111/all.14238.
    1. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05991-x.
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. 2020 doi: 10.1001/jamainternmed.2020.0994.
    1. Mo P., Xing Y., Xiao Y., Deng L., Zhao Q., Wang H. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa270.
    1. Shi Y., Yu X., Zhao H., Wang H., Zhao R., Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24:108. doi: 10.1186/s13054-020-2833-7.
    1. Zhang X., Cai H., Hu J., Lian J., Gu J., Zhang S. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.03.040.
    1. Deng Y., Liu W., Liu K., Fang Y.-Y., Shang J., Zhou L. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J. 2020 doi: 10.1097/CM9.0000000000000824.
    1. Wan S., Xiang Y., Fang W., Zheng Y., Li B., Hu Y. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020 doi: 10.1002/jmv.25783.
    1. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.
    1. Wang L., He W., Yu X., Hu D., Bao M., Liu H. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 doi: 10.1016/j.jinf.2020.03.019.
    1. Wang L., Li X., Chen H., Yan S., Li D., Li Y. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from wuhan, China. Am J Nephrol. 2020:1–6. doi: 10.1159/000507471.
    1. Cai Q., Huang D., Ou P., Yu H., Zhu Z., Xia Z. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020 doi: 10.1111/all.14309.
    1. Cao J., Tu W.-J., Cheng W., Yu L., Liu Y.-K., Hu X. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in wuhan, China. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa243.
    1. Wang X., Fang J., Zhu Y., Chen L., Ding F., Zhou R. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect. 2020 doi: 10.1016/j.cmi.2020.03.032.
    1. Wang Y., Lu X., Chen H., Chen T., Su N., Huang F. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020 doi: 10.1164/rccm.202003-0736LE.
    1. Du R.-H., Liang L.-R., Yang C.-Q., Wang W., Cao T.-Z., Li M. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020 doi: 10.1183/13993003.00524-2020.
    1. Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. doi: 10.1016/j.jcv.2020.104364.
    1. Zheng F., Tang W., Li H., Huang Y.-X., Xie Y.-L., Zhou Z.-G. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24:3404–3410. doi: 10.26355/eurrev_202003_20711.
    1. Simonnet A., Chetboun M., Poissy J., Raverdy V., Noulette J., Duhamel A. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020 doi: 10.1002/oby.22831.
    1. Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020 doi: 10.1164/rccm.202002-0445OC.
    1. Yang Z., Shi J., He Z., Lü Y., Xu Q., Ye C. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020;12:6037–6048. doi: 10.18632/aging.102999.
    1. Liu Y., Du X., Chen J., Jin Y., Peng L., Wang H.H.X. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.002.
    1. Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.1127.
    1. Shen L., Li S., Zhu Y., Zhao J., Tang X., Li H. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei province, China. J Infect. 2020 doi: 10.1016/j.jinf.2020.03.038.
    1. Zhang R., Ouyang H., Fu L., Wang S., Han J., Huang K. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol. 2020 doi: 10.1007/s00330-020-06854-1.
    1. Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 doi: 10.1016/j.jaci.2020.04.006.
    1. Wei Y.-Y., Wang R.-R., Zhang D.-W., Tu Y.-H., Chen C.-S., Ji S. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.010.
    1. Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020 doi: 10.1111/bjh.16659.
    1. Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R., Jabri A. Clinical characteristics of covid-19 in New York city. N Engl J Med. 2020 doi: 10.1056/NEJMc2010419.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit